Mishra Akanksha, Krishnamurthy Sairam
Department of Pharmacology, Institute of Pharmaceutical Sciences, University of Lucknow, Lucknow-226031, U.P., India.
Neurotherapeutics Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi-221005, U.P., India.
Iran J Basic Med Sci. 2024;27(11):1357-1369. doi: 10.22038/ijbms.2024.77760.16826.
Medicinal plants and phytochemicals are some of the major sources in the treatment of various neurodegenerative disorders including Alzheimer's disease (AD). There is no FDA-approved drug to target AD pathology directly. Full cognitive restoration and management of psychosis-like symptoms are still to be achieved. Being comparatively safer with fewer side effects, medicinal plants have been among the major areas of interest to be researched. Several mechanistic pathways are involved in AD including anticholinesterase activity, glutamate toxicity, free radicals generation, Amyloid β (Aβ) toxicity, inflammation, and mitochondrial dysfunction. Various phytochemicals such as paenol, andrographolide, isoquercitrin, flavonoids, and saponins obtained from different plant sources, various medicinal plants like as well as various traditional medicinal plants of China, Asia, Europe, Turkey, and Iran have been found effective against one or more of these targets. Large numbers of clinical trials are under process to evaluate the role of different phytoconstituents in AD management. Out of 143 agents under clinical trials, 119 have been categorized as disease-modifying agents. The present review extensively covers the recent advancements in the usage of phytochemicals and medicinal plants in various experimental AD models. It involves clinical trials and other research works divided into three sections, including those performed , and in humans mainly from the last five years along with disease markers and mechanistic pathways involved. However, phytochemicals should be explored further in order to achieve neurorestoration in AD.
药用植物和植物化学物质是治疗包括阿尔茨海默病(AD)在内的各种神经退行性疾病的一些主要来源。目前尚无美国食品药品监督管理局(FDA)批准的直接针对AD病理的药物。全面的认知恢复和精神病样症状的管理仍有待实现。药用植物相对更安全,副作用更少,一直是研究的主要关注领域之一。AD涉及多种机制途径,包括抗胆碱酯酶活性、谷氨酸毒性、自由基生成、β淀粉样蛋白(Aβ)毒性、炎症和线粒体功能障碍。从不同植物来源获得的各种植物化学物质,如丹皮酚、穿心莲内酯、异槲皮苷、黄酮类化合物和皂苷,以及中国、亚洲、欧洲、土耳其和伊朗的各种药用植物,已被发现对这些靶点中的一个或多个有效。大量临床试验正在进行中,以评估不同植物成分在AD管理中的作用。在143种正在进行临床试验的药物中,119种已被归类为疾病修饰药物。本综述广泛涵盖了植物化学物质和药用植物在各种实验性AD模型中应用的最新进展。它涉及临床试验和其他研究工作,分为三个部分,包括主要在过去五年中进行的动物实验和人体实验,以及涉及的疾病标志物和机制途径。然而,为了在AD中实现神经修复,仍需进一步探索植物化学物质。